AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21819308 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringes stored on ice (SI)
Number of subjects: 80
Study 21819308 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 18805887 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous work pattern (three periods of 40 continuous minutes for each task)
Number of subjects: 24
Study 18805887 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous work pattern (40 min tasks divided into four periods of 4, 8, 12 and 16 min)
Number of subjects: 24
Study 17259696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg/day for 12 weeks
Number of subjects: 50
Study 17259696 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ALA treatment)
Number of subjects: 50
Study 15175628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (arranging follow-up appointments from the hospital)
Number of subjects: 328
Study 15175628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no arrangement of follow-up appointments)
Number of subjects: 328
Study 11756055 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 46
Study 11756055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, complex carbohydrate diet (LF-CC)
Number of subjects: 46
Study 11756055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, simple carbohydrate diet (LF-SC)
Number of subjects: 46
Study 9803986 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (oral or intramuscular doses weekly)
Number of subjects: 62
Study 7659386 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet nebulizer (Respirgard II) with 2 ml volume fill (R2)
Number of subjects: 5
Study 7659386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer (Ultraneb 99) with 4 ml volume fill (U4)
Number of subjects: 5
Study 2473364 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP‐B
Number of subjects: 60
Study 2473364 — intervention group
Group type: COMPARATOR
Intervention: CEOP‐B
Number of subjects: 60
Study 937876 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutored physicians
Number of subjects: 0
Study 937876 — intervention group
Group type: COMPARATOR
Intervention: Control physicians (untutored)
Number of subjects: 0
Study 31847915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Laser Group (n=26) treated with 3 J/cm2
Number of subjects: 100
Study 31847915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Ultrasound Group (n=24) treated with 1 W/cm2 at 3 MHz
Number of subjects: 100
Study 31847915 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Ultrasound Group (n=26) treated with 1 W/cm2 at 1 MHz
Number of subjects: 100
Study 31847915 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n=24)
Number of subjects: 100
Study 28940709 — intervention group
Group type: EXPERIMENTAL
Intervention: Encode protocol
Number of subjects: 44
Study 28940709 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 44
Study 26037798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine (CisGem) chemotherapy
Number of subjects: 462
Study 23569146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) for 12 weeks
Number of subjects: 27
Study 23569146 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone (non‐CRT group)
Number of subjects: 27
Study 23569146 — intervention group
Group type: COMPARATOR
Intervention: Controls (n = 20)
Number of subjects: 27
Study 21320331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based intensive lifestyle counseling alone (n = 80)
Number of subjects: 200
Study 21320331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based intensive lifestyle counseling combined with community health worker support (n = 80)
Number of subjects: 200
Study 21320331 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (n = 40)
Number of subjects: 200
Study 19165639 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (three brisk walks and 1-2 aerobic exercises/week for one year)
Number of subjects: 112
Study 19165639 — intervention group
Group type: COMPARATOR
Intervention: Control (normal sedentary life)
Number of subjects: 112
Study 19165639 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 112
Study 19165639 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training and Control
Number of subjects: 112
Study 17093157 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood sampling with glucose as the reference food
Number of subjects: 12
Study 17093157 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood sampling with white bread as the reference food
Number of subjects: 12
Study 17093157 — intervention group
Group type: COMPARATOR
Intervention: Venous blood sampling
Number of subjects: 12
Study 17093157 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tests of glucose solution as the reference
Number of subjects: 12
Study 17093157 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing white bread as the reference 1, 2, or 3 times
Number of subjects: 12
Study 15286687 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) alone
Number of subjects: 34
Study 15286687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) and Cyclosporin A (CsA) combination
Number of subjects: 34
Study 11331446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion-implanted CVAD
Number of subjects: 106
Study 11331446 — intervention group
Group type: COMPARATOR
Intervention: Standard CVAD
Number of subjects: 106
Study 9394582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin discontinued two days before operation (Group I)
Number of subjects: 22
Study 9394582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin continued up to operation (Group II)
Number of subjects: 22
Study 9394582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin for at least seven days before operation)
Number of subjects: 22
Study 7965266 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 7965266 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0
Study 7965266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 3678266 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (450 mg to 900 mg per day)
Number of subjects: 16
Study 3678266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29082595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (25 ml beetroot juice, one shot per day for 3 days)
Number of subjects: 7
Study 27207917 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 27207917 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 0
Study 25153949 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-session positive psychology group intervention (n = 87)
Number of subjects: 175
Study 25153949 — intervention group
Group type: COMPARATOR
Intervention: Wait list group (n = 88)
Number of subjects: 175
Study 22578685 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Number of subjects: 125
Study 22578685 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 125
Study 19947907 — intervention group
Group type: EXPERIMENTAL
Intervention: SC ceftriaxone with rHuPH20 (350 mg/mL)
Number of subjects: 54
Study 19947907 — intervention group
Group type: COMPARATOR
Intervention: SC ceftriaxone preceded by placebo
Number of subjects: 54
Study 19947907 — intervention group
Group type: COMPARATOR
Intervention: IV ceftriaxone
Number of subjects: 54
Study 19947907 — intervention group
Group type: EXPERIMENTAL
Intervention: SC ceftriaxone (with or without rHuPH20)
Number of subjects: 54
Study 18422695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX mouthwash with anti discoloration system (ADS)
Number of subjects: 48
Study 18422695 — intervention group
Group type: COMPARATOR
Intervention: 0.2% CHX mouthwash without anti discoloration system (ADS)
Number of subjects: 48
Study 15655130 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d
Number of subjects: 58
Study 15655130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid 300 mg/d
Number of subjects: 58
Study 15655130 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d and Lipoic acid 300 mg/d
Number of subjects: 58
Study 15655130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 12805489 — intervention group
Group type: EXPERIMENTAL
Intervention: UK‐279,276 (1.0 mg/kg)
Number of subjects: 176
Study 12805489 — intervention group
Group type: EXPERIMENTAL
Intervention: UK‐279,276 (1.5 mg/kg)
Number of subjects: 176
Study 12805489 — intervention group
Group type: EXPERIMENTAL
Intervention: UK‐279,276 (0.06, 0.1, 0.2, 0.5, 1.0, 1.5 mg/kg)
Number of subjects: 176
Study 12805489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 12805489 — intervention group
Group type: EXPERIMENTAL
Intervention: UK‐279,276
Number of subjects: 176
Study 12805489 — intervention group
Group type: EXPERIMENTAL
Intervention: UK‐279,276 (1.0 and 1.5 mg/kg)
Number of subjects: 176
Study 11191952 — intervention group
Group type: EXPERIMENTAL
Intervention: Single booster vaccination (day 0)
Number of subjects: 185
Study 11191952 — intervention group
Group type: EXPERIMENTAL
Intervention: Two booster vaccinations (day 0, 28)
Number of subjects: 185
Study 11191952 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (single and two boosters)
Number of subjects: 185
Study 11191952 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 185
Study 8606643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CRF/AVP test (100 micrograms CRF plus 0.3 IU AVP IV)
Number of subjects: 3
Study 8606643 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized stress test (puzzles and mental arithmetic)
Number of subjects: 3
Study 8606643 — intervention group
Group type: COMPARATOR
Intervention: Control saline test
Number of subjects: 3
Study 8606643 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress test
Number of subjects: 3
Study 8606643 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective emotional involvement during stressful tasks
Number of subjects: 3
Study 1610575 — intervention group
Group type: EXPERIMENTAL
Intervention: Early anesthesia evaluation (1 to 7 days preoperative)
Number of subjects: 63
Study 1610575 — intervention group
Group type: COMPARATOR
Intervention: Day-of-surgery evaluation
Number of subjects: 63
Study 6208468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclocytidine (Cyclo‐C)
Number of subjects: 130
Study 6208468 — intervention group
Group type: COMPARATOR
Intervention: Cytosine arabinoside (Ara‐C) given every 12 hr
Number of subjects: 130
Study 6208468 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with cyclophosphamide combined with Ara‐C
Number of subjects: 130
Study 6208468 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with Cyclo‐C
Number of subjects: 130
Study 6208468 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of VP‐16 and CCNU to maintenance therapy
Number of subjects: 130
Study 31629944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre/interconception health intervention delivered during pediatric primary care
Number of subjects: 415
Study 31629944 — intervention group
Group type: COMPARATOR
Intervention: Usual care comparison group
Number of subjects: 415
Study 31629944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre/interconception health intervention
Number of subjects: 415
Study 31233859 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids SIPsmartER program (6-month school-based behavior and health literacy program)
Number of subjects: 12
Study 31233859 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids SIPsmartER program
Number of subjects: 12
Study 31233859 — intervention group
Group type: COMPARATOR
Intervention: Control schools (not receiving Kids SIPsmartER)
Number of subjects: 12
Study 28145073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermalax implant plus™
Number of subjects: 52
Study 28145073 — intervention group
Group type: COMPARATOR
Intervention: Restylane Sub‐Q®
Number of subjects: 52
Study 26269089 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CGF (test; 60 defects)
Number of subjects: 20
Study 26269089 — intervention group
Group type: COMPARATOR
Intervention: CAF (control; 59 defects)
Number of subjects: 20
Study 23863816 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist
Number of subjects: 6
Study 23863816 — intervention group
Group type: COMPARATOR
Intervention: Pressure support (PSinit)
Number of subjects: 6
Study 23863816 — intervention group
Group type: COMPARATOR
Intervention: Pressure support (PSbest)
Number of subjects: 6
Study 21610420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoaneurysm screening (PSA-S) for grades IV and V injuries
Number of subjects: 0
Study 21610420 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial angioembolization (IE) for grade IV and V injuries
Number of subjects: 0
Study 21610420 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep venous thrombosis prophylaxis (DVT-P)
Number of subjects: 0
Study 21610420 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation only for grades I and II injuries
Number of subjects: 0
Study 19705681 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated ICPS drug and employment counseling (n = 12)
Number of subjects: 23
Study 19705681 — intervention group
Group type: COMPARATOR
Intervention: ICPS drug counseling control condition (n = 11)
Number of subjects: 23
Study 17012300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg intravenous infusion over 30 min)
Number of subjects: 104
Study 12431972 — intervention group
Group type: EXPERIMENTAL
Intervention: Study agent (cytostatic agent)
Number of subjects: 0
Study 12431972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9927265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vancomycin (500 mg/d)
Number of subjects: 0
Study 9927265 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vancomycin (2 g/d)
Number of subjects: 0
Study 9927265 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1 g/d)
Number of subjects: 0
Study 9927265 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 8745203 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 27
Study 8745203 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and sulfonylurea
Number of subjects: 27
Study 2040035 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 40 mg/m2
Number of subjects: 78
Study 2040035 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2
Number of subjects: 78
Study 2040035 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2
Number of subjects: 78
Study 2040035 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 135 mg/m2
Number of subjects: 78
Study 2040035 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 78
Study 7004720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (10 mg daily) for 3 days
Number of subjects: 0
Study 7004720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (10 mg daily) for 10 weeks
Number of subjects: 0
Study 6882732 — intervention group
Group type: EXPERIMENTAL
Intervention: Malted cocoa drink fortified with FePO4 and ascorbic acid (1 mg/g powder)
Number of subjects: 0
Study 6882732 — intervention group
Group type: EXPERIMENTAL
Intervention: Malted cocoa drink fortified with FePO4
Number of subjects: 0
Study 6882732 — intervention group
Group type: EXPERIMENTAL
Intervention: Malted cocoa drink fortified with FeSO4
Number of subjects: 0
Study 6882732 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 0
Study 31069575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone for 52 weeks
Number of subjects: 0
Study 31069575 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 52 weeks
Number of subjects: 0
Study 29490721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-supplemented granola bar (OF-Bar)
Number of subjects: 55
Study 29490721 — intervention group
Group type: COMPARATOR
Intervention: Control granola bar (Co-Bar)
Number of subjects: 55
Study 26758281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebselen (3600 mg over 24 h)
Number of subjects: 20
Study 26758281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to ebselen)
Number of subjects: 20
Study 24574355 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12537
Study 24574355 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12537
Study 24574355 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 12537
Study 24574355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12537
Study 22009510 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg oral naproxen sodium plus active TENS
Number of subjects: 65
Study 22009510 — intervention group
Group type: COMPARATOR
Intervention: 550 mg oral naproxen sodium plus placebo TENS
Number of subjects: 65
Study 20493632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 217
Study 20493632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 18581586 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of parecoxib
Number of subjects: 50
Study 18581586 — intervention group
Group type: COMPARATOR
Intervention: 2 g of proparacetamol
Number of subjects: 50
Study 15781816 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray Matter Fraction (GMF) in RRMS patients
Number of subjects: 21
Study 15781816 — intervention group
Group type: EXPERIMENTAL
Intervention: White Matter Fraction (WMF) in RRMS patients
Number of subjects: 21
Study 15781816 — intervention group
Group type: EXPERIMENTAL
Intervention: White Matter Fraction (WMF) in RRMS patients with largest decline in Gd volume
Number of subjects: 21
Study 15781816 — intervention group
Group type: EXPERIMENTAL
Intervention: White Matter Fraction (WMF) in RRMS patients with increased Gd-enhancing lesions
Number of subjects: 21
Study 12902996 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 19
Study 12902996 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (Control)
Number of subjects: 19
Study 10500010 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat test breakfasts (4 different breakfasts)
Number of subjects: 91
Study 10500010 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control breakfast
Number of subjects: 91
Study 8628042 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item short-form (SF-12)
Number of subjects: 2333
Study 8628042 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item Physical Component Summary
Number of subjects: 2333
Study 8628042 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item Mental Component Summary
Number of subjects: 2333
Study 8628042 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item short-form
Number of subjects: 2333
Study 1909444 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 0
Study 1909444 — intervention group
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Number of subjects: 0
Study 7168548 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 33
Study 7168548 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 33
Study 30774288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure injury prevention intervention program
Number of subjects: 50
Study 29382298 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of high-intensity treadmill training embedded in self-management education
Number of subjects: 128
Study 29382298 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy gait training
Number of subjects: 128
Study 26739742 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 120
Study 26739742 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 120
Study 24685996 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary team of a nurse, occupational therapist, and handyman
Number of subjects: 0
Study 24685996 — intervention group
Group type: COMPARATOR
Intervention: Attention control of sedentary activities of choice
Number of subjects: 0
Study 22108444 — intervention group
Group type: EXPERIMENTAL
Intervention: 80mg simvastatin
Number of subjects: 650
Study 22108444 — intervention group
Group type: COMPARATOR
Intervention: 40mg simvastatin
Number of subjects: 650
Study 22108444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study 20179234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 912
Study 20179234 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant endocrine treatment
Number of subjects: 912
Study 17010685 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/day)
Number of subjects: 2617
Study 17010685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2617
Study 15983347 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (details not specified)
Number of subjects: 0
Study 15983347 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (details not specified)
Number of subjects: 0
Study 12172717 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam in 25 ml normal saline
Number of subjects: 42
Study 12172717 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine in 25 ml normal saline
Number of subjects: 42
Study 12172717 — intervention group
Group type: COMPARATOR
Intervention: 25 ml normal saline (control)
Number of subjects: 42
Study 10199760 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 16
Study 10199760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion (10% at 150 mL/h)
Number of subjects: 16
Study 10199760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16